Dispenzieri, Angela

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

Fonseca, R., Van Wier, S. A., Chng, W. J., Ketterling, R., Lacy, M. Q., Dispenzieri, A., Bergsagel, P. L., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., et al. (2006) · Leukemia

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 213

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 197

Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Rosiñol, L., Beksac, M., Zamagni, E., Van de Donk, N. W. C. J., Anderson, K. C., Badros, A., Caers, J., Cavo, M., Dimopoulos, M., Dispenzieri, A., et al. (2021) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 179

Artificial Intelligence–Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis

Grogan, M., Lopez-Jimenez, F., Cohen-Shelly, M., Dispenzieri, A., Attia, Z. I., Abou Ezzedine, O. F., Lin, G., Kapa, S., Borgeson, D. D., Friedman, P. A., et al. (2021) · Mayo Clinic Proceedings

Amyloidosis: Diagnosis, Treatment, OutcomesECG Monitoring and Analysis

Cited by 166

MYC dysregulation in the progression of multiple myeloma

MMRF CoMMpass Network, Misund, K., Keane, N., Stein, C. K., Asmann, Y. W., Day, G., Welsh, S., Van Wier, S. A., Riggs, D. L., Ahmann, G., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 161

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

Gonsalves, W. I., Leung, N., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Dingli, D., Kapoor, P., Go, R. S., et al. (2015) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsRenal cell carcinoma treatment

Cited by 133

Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement

Murray, D., Kumar, S. K., Kyle, R. A., Dispenzieri, A., Dasari, S., Larson, D. R., Vachon, C., Cerhan, J. R., & Rajkumar, S. V. (2019) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 102

Clinical course and prognosis of non‐secretory multiple myeloma

Chawla, S. S., Kumar, S. K., Dispenzieri, A., Greenberg, A. J., Larson, D. R., Kyle, R. A., Lacy, M. Q., Gertz, M. A., & Rajkumar, S. V. (2015) · European Journal of Haematology

Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 88

Uncovering the biology of multiple myeloma among African Americans: A comprehensive genomics approach

Baker, A., Braggio, E., Jacobus, S., Jung, S., Larson, D., Therneau, T., Dispenzieri, A., Van Wier, S. A., Ahmann, G., Levy, J., et al. (2013) · Blood

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 66

Vascular abnormalities in primary amyloidosis

Modesto, K. M., Dispenzieri, A., Gertz, M., Cauduro, S. A., Khandheria, B. K., Seward, J. B., Kyle, R., Wood, C. M., Bailey, K. R., Tajik, A. J., et al. (2007) · European Heart Journal

Amyloidosis: Diagnosis, Treatment, OutcomesCardiovascular Health and Disease Prevention

Cited by 65

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

Madan, S., Lacy, M. Q., Dispenzieri, A., Gertz, M. A., Buadi, F., Hayman, S. R., Detweiler-Short, K., Dingli, D., Zeldenrust, S., Lust, J., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 60

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma

Vu, T., Gonsalves, W., Kumar, S., Dispenzieri, A., Lacy, M. Q., Buadi, F., Gertz, M. A., & Rajkumar, S. V. (2015) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 51

Postdevelopment Performance and Validation of the Artificial Intelligence-Enhanced Electrocardiogram for Detection of Cardiac Amyloidosis

Harmon, D. M., Mangold, K., Baez Suarez, A., Scott, C. G., Murphree, D. H., Malik, A., Attia, Z. I., Lopez-Jimenez, F., Friedman, P. A., Dispenzieri, A., et al. (2023) · JACC: Advances

Amyloidosis: Diagnosis, Treatment, OutcomesECG Monitoring and Analysis

Cited by 47

Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Durie, B. G., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 34

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., et al. (2023) · Haematologica

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 9

Alzheimer’s disease genetics converges on microglial and neuronal dysregulation

Uffelmann, E., Wightman, D. P., Bahrami, S., Shadrin, A. A., Fominykh, V., Ojima, T., Jiang, C., Benner, C., Moreno, E., Campos, A. I., et al. (2026) · Nature

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 0